Announcement no. 21/2007

To OMX The Nordic Exchange, Copenhagen, and the press

Vedbæk, 27 November 2007

Exiqon - Interim report for the first 9 months of 2007 (unaudited)

Summary: Exiqon generated revenue of DKK 30 million, of which product sales amounted to DKK 21 million. Operating expenses amounted to DKK 81 million, and the loss for the period totalled DKK 47 million. Exiqon today announces its intention to acquire privately held Oncotech Inc., a diagnostic company, in a separate announcement.

Highlights

- Revenue increased by 54% on the same period of last year to DKK 30 million in the first nine months of 2007.
- Growth in product sales to DKK 21 million in the first nine months of 2007, a 62% increase on the year-earlier period.
- Increase in margin on product sales, including services, to 31% (23% in the same period of 2006, total gross margin of 51% against 48% in the year-earlier period).
- Total operating expenses of DKK 81 million, and a net loss of DKK 47 million.
- Exiqon updates its forecast for the financial year.

Status

The sale of research products traditionally is weak in the third quarter and this was also the case in 2007. However, product sales continue to show strong growth during the first 9 months of 2007 with an increase of 62% to the year earlier period. US sales did not meet expectations in the third quarter. However, Exiqon maintains its overall expectations to the financial outlook for 2007, except that revenues are now expected in the region of DKK 50-55 million, with product sales contributing DKK 40-45 million compared to earlier expectations of revenue in the region of DKK 55 million, with product sales contributing DKK 45 million. The loss for the year is expected to be in the region of DKK 50-55 million compared to earlier expectations of a loss for the year in the region of DKK 50 million. Exiqon today announces its intention to acquire privately held Oncotech Inc., a diagnostic company, in a separate announcement. The acquisition will strengthen Exiqon's presence in the US market considerably thereby adding further business opportunities also to the existing business.

During the third quarter, Exiqon strengthened its product offering within its tool business: On 10 July 2007, Exiqon entered in to a distribution agreement with Luminex under which Exiqon has obtained non-exclusive rights to distribute current and new FlexmiR products and to sell Luminex® systems to laboratories around the world. In September 2007, Exiqon launched its new miRCURY™ LNA Array product line. The product launch was followed up by a marketing campaign to secure a continued strong position on the US market in particular, including fully sponsored inlets in both Nature and Science. The preparations for additional product launches are on schedule and Exiqon expects before year end to launch a new product line for quantitative real-time PCR-detection thereby realising its strategy of becoming a total solution provider of research products for miRNA analysis.

The organisation grew with an additional 11 employees, 6 of which were hired in R&D in support of the development of diagnostic products based on miRNA.

Today, the organisation has 89 employees compared to 71 employees at the time the company went public in May 2007.

Events that has occurred after 30 September 2007

- On 18 September, Exiqon announced that Per Wold-Olsen has accepted to candidate for Exiqon's Board of Directors at the next Annual Meeting

- In October, Exiqon received confirmation that the company had been selected to receive funding by the EU for two research projects within miRNA over the coming 4-5 years at a combined value of approximately DKK 7 million; one project - OncomiR – focuses on basic research and the other project – ProspeR – focuses on diagnostic methods within in prostate cancer.

- On 16 October, Exiqon announced it had signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop microRNA-based diagnostics for colon cancer.

- On 6 November 2007, Exiqon announced that it had granted a license to Applied Biosystems (NYSE:ABI) an Applera Corporation business, to use Exiqon's proprietary Locked Nucleic Acids (LNA™) in siRNA.

- On 19 November, Exiqon announced that it has signed an agreement to exclusively license a microRNA quantitative real-time PCR technology from Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK) that provides Exiqon A/S with a validated product portfolio for quantitative analysis of miRNA planned for release later this year. Exiqon has also obtained a license to parts of Roche's and Applied Biosystems' PCR patent portfolio providing Exiqon with the opportunity to market this product line and other products for quantitative analysis of miRNA using real-time qPCR technology. An installed base of more than 20,000 real-time PCR instruments exist within research and diagnostic laboratories around the world making this method the most wide spread for quantitative measurements of DNA and RNA.

Comments on the interim report for the first 9 months of 2007
Revenue totalled DKK 29.5 million in the first 9 months of 2007 compared to DKK 19.2 million in the same period of 2006, representing an increase of 54%. The improvement is mainly attributable to a DKK 8.1 million increase in product sales, or 62% relative to the year-earlier period, and an increase in income from contract research of DKK 1.2 million, corresponding to 52%. The improved product sales are mainly due to increased sales activities and continuing growth in the market. The higher income from contract research is from collaboration agreements. The revenue in the third quarter is negatively affected by a retrospective price adjustment of part of the sales realized in 2006, which also affects the gross profit negatively.

Gross profit totalled DKK 14.9 million in the first 9 months of 2007 compared to DKK 9.2 million in the same period of 2006, representing an increase of 62%. The gross margin increased to 51% from 48% in the first 9 months of 2006. The improved gross profit is primarily attributable to higher revenue, while contract research was the primary contributor to the improved gross margin. The margin on product sales including services rose to 31% from 23% in the same period of last year.

Research and development costs totalled DKK 20.2 million in the first 9 months of 2007 compared to DKK 15.6 million in the same period of 2006, representing an increase of 29%. Research and development costs are charged with DKK 0.1 million in respect of share-based payment. Net of this charge, research and development costs totalled DKK 20.1 million in the first 9 months of 2007 compared to DKK 15.3 million in the same period of 2006, or an increase of 31%. The increase is mainly explained by a higher level of activity and recruitments relative to the year-earlier period.

Sales and marketing costs and administrative expenses totalled DKK 46.7 million in the first 9 months of 2007 compared to DKK 19.5 million in the same period of 2006, representing an increase of 139% (122% without the effect of share-based payment):

Sales and marketing costs rose 107% to DKK 23.8 million in the first 9 months of 2007 from DKK 11.5 million in the same period of 2006. Sales and marketing costs are charged with DKK 0.6 million in respect of share-based payment. Net of this charge, sales and marketing costs totalled DKK 23.2 million in the first 9 months of 2007 compared to DKK 11.4 million in the same period of 2006, or an increase of 104%. The increase relative to the year-earlier period was mainly due to the establishment of the company's own sales organisation in the United States as well as an expansion of our sales organisation and sales activities in Denmark.

Administrative expenses totalled DKK 22.9 million in the first 9 months of 2007 against DKK 8.0 million in the same period of 2006, representing a planned increase that amounted to 186%. Administrative expenses are charged with DKK 6.4 million in respect of share-based payment. Net of this charge, administrative expenses totalled DKK 16.5 million in the first 9 months of 2007 compared to DKK 6.0 million in the same period of 2006, or an increase of 175%. The increase is mainly due to an increase in the administrative staff as well as a reorganisation of the IT-function, as a result of which a larger part of IT costs is now recognised as administrative expenses as compared with the same period of 2006. Administrative expenses are furthermore charged with one-off expenses of DKK 4.5 million as a result of a restructuring and strengthening of the organisation.

Operating costs totalled DKK 81.5 million in the first 9 months of 2007 compared to DKK 45.2 million in the same period of 2006, representing an increase of 80%. Operating costs are charged with DKK 7.2 million in respect of share-based payment. Net of this charge, operating costs totalled DKK 74.3 million in the first 9 months of 2007 compared to DKK 42.6 million in the same period of 2006, representing an increase of 74%.

Net financial income totalled DKK 5.0 million in the first 9 months of 2007 compared to DKK 0.2 million in the same period of 2006. Financial income mainly consists of interest on fixed-term deposit accounts, while financial expenses mainly consist of interest on financial lease agreements.

The net loss for the first 9 months of 2007 totalled DKK 47.0 million compared to DKK 25.8 million in the same period of 2006. The financial performance is consistent with our expectations.

Net cash flows were positive in the amount of DKK 338.4 million in the first 9 months of 2007 compared to a net cash outflow of DKK 9.4 million in the same period of 2006. The increase is mainly due to the proceeds from the initial public offering.

As of 30 September 2007, cash and cash equivalents totalled DKK 358.4 million compared to DKK 31.2 million as of 30 September 2006.

Outlook for the 2007 financial year
For 2007, Exiqon expects revenue in the region of DKK 50-55 million, with product sales contributing DKK 40-45 million.

Operating expenses will be in the region of DKK 115 million, of which sales and marketing costs and administrative expenses are expected to account for DKK 65 million.

An operating loss in the region of DKK 60 million is expected. This includes costs of incentive plans, including warrants, in the amount of DKK 9.6 million.

The loss for the year is expected to be in the region of DKK 50-55 million.

Directors' and Management's statement on the interim report
The Board of Directors and the Executive Management have today considered and adopted the interim report of Exiqon A/S for the period 1 January – 30 September 2007.

The interim report is prepared in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim report is unaudited.

We consider the accounting policies to be appropriate, the accounting estimates made to be reasonable and the overall presentation of the interim report to be adequate, so that the interim report, in our opinion, gives a true and fair view of the assets, liabilities, financial position, and results of operations and cash flows of the group for the period 1 January – 30 September 2007.

Vedbæk, 27 November 2007

Executive Management

Lars Kongsbak

Board of Directors

Thorleif Krarup Chairman	Henrik Lawaetz Deputy Chairman	Steiner J. Engelsen
Michael Nobel	Erik Wallden	

Additional information:
Lars Kongsbak, CEO, telephone +45 45 66 08 88
Hans Henrik Chrois Christensen, CFO, telephone +45 45 66 08 88

Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company's actual results may differ materially from the information set forth in these statements.

This is an English translation of the interim report for the first 9 months of 2007 prepared in Danish. In case of any discrepancies between the Danish version and this English translation thereof, the Danish version shall prevail.

Key figures for the Exiqon Group (unaudited)

(DKK'000 million except key figures)	1 Jul. – 30 Sep. 2007	1 Jul. – 30 Sep. 2006	1 Jan. – 30 Sep. 2007	1 Jan. – 30 Sep. 2006	1 Jan. – 31 Dec. 2006
Income statement:					
Revenue	8,499	7,487	29,537	19,237	43,096
Production costs	-7,011	-4,870	-14,606	-10,016	-11,936
Research and development costs	-6,308	-4,745	-20,183	-15,646	-27,624
Sales and marketing costs	-8,684	-4,602	-23,785	-11,506	-19,425
Administrative expenses	-7,970	-3,859	-22,901	-8,039	-9,616
Operating profit (loss)	-21,474	-10,589	-51,938	-25,970	-25,505
Net financials	4,832	37	4,965	215	587
Profit/(loss) before tax	-16,642	-10,552	-46,973	-25,755	-24,918
Profit/(loss) for the period	-16,642	-10,552	-46,973	-25,755	-24,918
Balance sheet:					
Assets					
Intangible assets			7,574	1,227	8,057
Property, plant and equipment			16,002	8,542	10,607
Financial assets			2,162	1,455	1,055
Non-current assets			25,738	11,224	19,719
Inventories			5,058	2,938	4,637
Receivables			10,191	5,155	22,233
Cash and cash equivalents			358,397	31,246	20,396
Current assets			373,646	39,339	47,266
Total assets			399,384	50,563	66,985
Equity and liabilities:					
Equity			361,475	26,881	33,973
Non-current liabilities			8,677	3,666	5,275
Current liabilities			29,232	20,016	27,737
Total liabilities			37,909	23,682	33,012
Equity and liabilities			399,384	50,563	66,985
Cash flow statement:					
Cash flows from operating activities			-24,074	-27,844	-35,590
Investment in intangible assets and property, plant and equipment			-2,796	-1,750	-1,484
Cash flows from investing activities			-3,906	-2,327	-9,883
Cash flows from financing activities			366,367	20,808	25,670
Cash and cash equivalents at the end of period			358,397	31,246	20,396
Financial figures:					
Number of shares, end of period			24,406,802	6,939,375	7,033,065
Number of shares, average			18,821,200	6,934,918	6,940,420
Basic and diluted EPS	-0.88	-0.76	-2.50	-1.86	-1.80
Assets/Equity (gearing)			1.10	1.88	1.97
Average number of employees			75	46	62
Market price per share (DKK)			36.4		
Market capitalisation (DKK million)			888.4		
Price / net asset value			2.46		

Basic and diluted EPS have been calculated in accordance with IAS 33 "Earnings per share"
Other ratios have been calculated in accordance with "Recommendations & Financial Ratios 2005" issued by the Danish Society of Financial Analysts, dated December 2004

Income statement (unaudited)

(DKK'000)	Note	1 Jul. – 30 Sep. 2007	1 Jul. – 30 Sep. 2006	1 Jan. – 30 Sep. 2007	1 Jan. – 30 Sep. 2006	1 Jan. – 31 Dec. 2006
Revenue	2,3	8,499	7,487	29,537	19,237	43,096
Production costs		-7,011	-4,870	-14,606	-10,016	-11,936
Gross profit		**1,488**	**2,617**	**14,931**	**9,221**	**31,160**
Research and development costs		-6,308	-4,745	-20,183	-15,646	-27,624
Sales and marketing costs		-8,684	-4,602	-23,785	-11,506	-19,425
Administrative expenses		-7,970	-3,859	-22,901	-8,039	-9,616
Operating profit (EBIT)		**-21,474**	**-10,589**	**-51,938**	**-25,970**	**-25,505**
Financial income		4,999	105	5,541	387	1,159
Financial expenses		-167	-68	-576	-172	-572
Profit/(loss) before tax		**-16,642**	**-10,552**	**-46,973**	**-25,755**	**-24,918**
Tax on profit/(loss) for the period		0	0	0	0	0
Profit/(loss) for the period		**-16,642**	**-10,552**	**-46,973**	**-25,755**	**-24,918**
Basic and diluted EPS (DKK 1 per share)		-0.88	-0.76	-2.50	-1.86	-1.80

Balance sheet - assets (unaudited)

(DKK'000)	Note	30 Sep. 2007	30 Sep. 2006	31 Dec. 2006
Acquired patent rights		5,369	43	5,626
Acquired software licenses		2,205	1,184	2,431
Intangible assets		**7,574**	**1,227**	**8,057**
Leasehold improvements		2,977	1,852	2,217
Production and laboratory equipment		9,895	5,010	5,612
Fixtures and fittings, tools and equipment		3,130	1,680	2,778
Property, plant and equipment		**16,002**	**8,542**	**10,607**
Other securities and investments		0	400	0
Deposits		2,162	1,055	1,055
Financial assets		**2,162**	**1,455**	**1,055**
Total non-current assets		**25,738**	**11,224**	**19,719**
Inventories		**5,058**	**2,938**	**4,637**
Trade receivables		6,658	3,794	20,933
Other receivables		3,533	1,361	1,300
Receivables		**10,191**	**5,155**	**22,233**
Cash and cash equivalents	4	**358,397**	**31,246**	**20,396**
Current assets		**373,646**	**39,339**	**47,266**
Total assets		**399,384**	**50,563**	**66,985**

Balance sheet – equity and liabilities (unaudited)

(DKK'000)	30 Sep. 2007	30 Sep. 2006	31 Dec. 2006
Share capital	24,407	6,939	7,033
Other reserves	337,068	19,942	26,940
Equity	**361,475**	**26,881**	**33,973**
Other provisions	0	0	0
Finance lease liabilities	8,677	3,666	5,275
Non-current liabilities	**8,677**	**3,666**	**5,275**
Finance lease liabilities	2,002	1,260	1,639
Trade payables	6,620	1,984	5,802
Prepayments	11,352	12,965	13,343
Other payables	9,258	3,807	6,953
Current liabilities	**29,232**	**20,016**	**27,737**
Total liabilities	**37,909**	**23,682**	**33,012**
Equity and liabilities	**399,384**	**50,563**	**66,985**

Cash flow statement (unaudited)

(DKK'000)	1 Jan. – 30 Sep. 2007	1 Jan. – 30 Sep. 2006	1 Jan. – 31 Dec. 2006
Operating profit	-51,938	-25,970	-25,505
Depreciation	2,977	2,448	3,255
Non-cash adjustments	7,207	2,644	4,663
Change in inventories	-421	-587	-2,286
Change in receivables	12,004	-2,844	-19,922
Change in trade payables etc.	1,132	-3,750	3,618
	-29,039	**-28,059**	**-36,177**
Financial income	5,541	387	1,159
Financial expenses	-576	-172	-572
Cash flows from operating activities	**-24,074**	**-27,844**	**-35,590**
Acquisition of intangible assets	-226	0	-7,822
Acquisition of property, plant and equipment	-2,570	-1,750	-1,484
Acquisition of financial assets	-1,110	-577	-577
Cash flows from investing activities	**-3,906**	**-2,327**	**-9,883**
Proceeds from capital increase	402,071	21,594	26,595
Cost of capital increase	-34,345	0	0
Repayment, finance leases	-1,359	-786	-925
Cash flow from financing activities	**366,367**	**20,808**	**25,670**
Change in cash and cash equivalents	**338,387**	**-9,363**	**-19,803**
Cash and cash equivalents at the beginning of period	20,396	40,199	40,199
Unrealised currency gain/(loss)	-386	410	0
Cash and cash equivalents at the end of period	**358,397**	**31,246**	**20,396**

Statement of changes in equity (unaudited)

	Share capital	Share premium (DKK'000)	Other reserves (DKK'000)	Total (DKK'000)
Equity at 1 January 2007	**7,033,065**	**7,033**	**26,940**	**33,973**
Profit/(loss) for the period			-46,973	-46,973
Exchange adjustments relating to foreign subsidiaries			-459	-459
Total recognised income and expense for the period			**-47,432**	**-47,432**
Proceeds from capital increases	9,993,500	9,994	389,747	399,741
Costs in connection with capital increases			-34,345	-34,345
Warrant exercise	239,742	240	2,092	2,332
Issue of bonus shares	7,140,495	7,140	-7,140	0
Share-based payment			7,206	7,206
Other transactions	**17,373,737**	**17,374**	**357,560**	**374,934**
Equity at 30 September 2007	**24,406,802**	**24,407**	**337,068**	**361,475**
Equity at 1 January 2006	**5,958,294**	**5,958**	**22,028**	**27,986**
Profit/(loss) for the period			-25,755	-25,755
Exchange adjustments relating to foreign subsidiaries			411	411
Total recognised income and expense for the period			**-25,344**	**-25,344**
Proceeds from capital increases	963,254	963	20,229	21,192
Costs in connection with capital increases				0
Warrant exercise	17,827	18	385	403
Share-based payment			2,644	2,644
Other transactions	**981,081**	**981**	**23,258**	**24,239**
Equity at 30 September 2006	**6,939,375**	**6,939**	**19,942**	**26,881**

Notes to the interim financial statements

Note 1 Accounting policies

The interim report of the Exiqon Group for the period 1 January – 30 September 2007 has been presented in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies.

The accounting policies applied to the interim financial statements are consistent with those applied to the annual report for the financial year 2006.

After the annual report for the financial year 2006 was presented, the International Accounting Standards Board (IASB) has issued new and revised Standards and Interpretations. It is Management's opinion that these new Standards and Interpretations will not have any effect on the Group's financial statements.

Note 2 Revenue

(DKK'000)	1 Jul. – 30 Sep. 2007	1 Jul. – 30 Sep. 2006	1 Jan. – 30 Sep. 2007	1 Jan. – 30 Sep. 2006	1 Jan. – 31 Dec. 2006
Product sales	6,534	4,754	21,131	13,048	20,973
License income	1,965	1,312	4,771	3,799	18,667
Contract research	0	1,421	3,635	2,390	3,456
	8,499	**7,487**	**29,537**	**19,237**	**43,096**

Note 3 Segment information

Primary segment
The activities of the Exiqon Group are all in the business area "Research". Therefore the primary segment comprises only one segment.

Secondary
The revenue of the Exiqon Group is distributed as follows on geographical segments:

(DKK'000)	1 Jul. – 30 Sep. 2007	1 Jul. – 30 Sep. 2006	1 Jan. – 30 Sep. 2007	1 Jan. – 30 Sep. 2006	1 Jan. – 31 Dec. 2006
Europe	5,188	3,972	17,817	11,551	27,088
North America	2,987	3,355	10,547	6,944	15,340
Asia	324	160	1,173	742	668
	8,499	**7,487**	**29,537**	**19,237**	**43,096**

Note 4 Cash and cash equivalents

Cash and cash equivalents are mainly invested in short fixed-term deposits, which are regularly renewed. These deposits involve only limited risk.

Warrant status

	Executive Manage-ment	Board of Directors	Senior Employees	Others	Total
Outstanding warrants at 1 January 2007	538,342	52,000	460,870	476,028	1,527,240*)
Granted in the financial year	452,498	303,503	306,565	0	1,062,566
Exercised in the financial year	72,000	52,000	0	223,172	347,172
Expired in the financial year	0	0	0	3,140	3,140
Outstanding warrants at 30 September 2007	**918,840**	**303,503**	**767,435**	**249,716**	**2,239,494**

*) The number of outstanding shares as of 1 January 2007 is adjusted as a result of the issue of bonus shares on 2 May 2007.

As of 30 September 2007, the following warrant programmes are still outstanding:

Programme	Exercise price	Exercise period	Market value in DKK million *)
May 2006	9.50	4 weeks following the announcement of annual and interim financials statements	28.9
December 2006	9.50	4 weeks following the announcement of annual and interim financials statements	4.6
May 2007	41.00	4 weeks following the announcement of annual and interim financials statements	12.1
Total			**45.6**

*) The market value is calculated on the basis of the Black-Scholes formula for valuation of warrants. The calculations are based on the assumption of no dividend per share, a volatility of 50%, a risk-free interest rate of 4.25% per annum, and finally the share price of Exiqon on 30 September 2007, DKK 36.4 per share. The expected maturity is relative to the date of subscription.

Warrant programme granted in May 2006
Of warrants granted in May 2006 ¾ vested as of 30 September 2007 for the Executive Management and the Senior Employees, and warrants are fully vested for Others. The exercise period expires on 21 January 2011.

Warrant programme granted in December 2006
Of warrants granted in December 2006 ¾ vested as of 30 September 2007 for the Senior Employees and warrants are fully vested for Others (with the exception of one employee who has the same terms as a Senior Employee). The exercise period expires on 21 January 2011.

Warrant programme granted in May 2007
Warrants granted in May 2007 are divided into 36 tranches, with 1/36 vesting monthly over a 36 month period. The exercise period expires in 2010. The exercise price is 40 with a premium of 5% p.a. from the date of grant until exercise.